secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-06-30T12:30:18+00:00
Accession:  0001437749-26-022088
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim
----------------------------------------------------------------------------

- CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).
- iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.
- Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.
- Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/0001437749-26-022088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/mbrx20260630_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-022088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer